Skip to main content

NexImmune Announces Presentation of Preliminary Phase 1/2 Clinical Data at the 2021 American Society of Clinical Oncology Annual Meeting


GAITHERSBURG, Md., May 19, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced that clinical data from its Phase 1/2 dose escalation study of NEXI-001 will be presented in a poster session at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting being held virtually from June 4 – June 8, 2021.

Poster Presentation:

Title: Preliminary Analysis of a Phase 1/2 Study of NEXI-001 Donor-Derived Multi-Antigen-Specific CD8+ T Cell Treatment of Relapsed Acute Myeloid Leukemia (AML) After Allogeneic Hematopoietic Cell Transplantation (HCT)

Abstract #: 2538

Session Title: Poster Session: Developmental Therapeutics – Immunotherapy

Press Release